These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14586600)

  • 1. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis.
    Monaca-Charley C; Stojkovic T; Duhamel A; De Seze J; Ferriby D; Vermersch P
    J Neurol; 2003 Oct; 250(10):1190-4. PubMed ID: 14586600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of administration of dolasetron affects dose necessary to prevent postoperative nausea and vomiting.
    Korttila KT; Jokinen JD
    J Clin Anesth; 2004 Aug; 16(5):364-70. PubMed ID: 15374558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple-dose, placebo-controlled, phase I study of oral dolasetron.
    Hunt TL; Cramer M; Christy-Bittel J; Shah AK; Meyerson LJ; Benedict CR; Hahne WF
    Pharmacotherapy; 1996; 16(2):253-60. PubMed ID: 8820469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia.
    Vergne-Salle P; Dufauret-Lombard C; Bonnet C; Simon A; Trèves R; Bonnabau H; Bertin P
    Eur J Pain; 2011 May; 15(5):509-14. PubMed ID: 21036635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous dolasetron mesilate in the prevention of postoperative nausea and vomiting in females undergoing gynecological surgery.
    Diemunsch P; D'Hollander A; Paxton L; Schoeffler P; Wessel P; Navé S; Brown RA; Hahne WF
    J Clin Anesth; 1997 Aug; 9(5):365-73. PubMed ID: 9257201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting.
    Diemunsch P; Leeser J; Feiss P; D'Hollander A; Bradburn BG; Paxton D; Whitmore J; Panouillot P; Navé S; Brown RA; Hahne WF
    Can J Anaesth; 1997 Feb; 44(2):173-81. PubMed ID: 9043731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study.
    Bier JC; Dethy S; Hildebrand J; Jacquy J; Manto M; Martin JJ; Seeldrayers P
    J Neurol; 2003 Jun; 250(6):693-7. PubMed ID: 12796831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
    Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
    J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor.
    Rice GP; Lesaux J; Vandervoort P; Macewan L; Ebers GC
    J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):282-4. PubMed ID: 9069487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia.
    Späth M; Stratz T; Neeck G; Kötter I; Hammel B; Amberger CC; Haus U; Färber L; Pongratz D; Müller W
    Scand J Rheumatol; 2004; 33(4):267-70. PubMed ID: 15370724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
    Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
    Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.
    Späth M; Welzel D; Färber L
    Scand J Rheumatol Suppl; 2000; 113():72-7. PubMed ID: 11028837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype.
    Janicki PK; Schuler HG; Jarzembowski TM; Rossi M
    Anesth Analg; 2006 Apr; 102(4):1127-33. PubMed ID: 16551910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The addition of dexamethasone to dolasetron or haloperidol for treatment of established postoperative nausea and vomiting.
    Rüsch D; Arndt C; Martin H; Kranke P
    Anaesthesia; 2007 Aug; 62(8):810-7. PubMed ID: 17635430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolasetron for preventing postanesthetic shivering.
    Piper SN; Röhm KD; Maleck WH; Fent MT; Suttner SW; Boldt J
    Anesth Analg; 2002 Jan; 94(1):106-11, table of contents. PubMed ID: 11772810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial.
    The GK; Bleijenberg G; Buitelaar JK; van der Meer JW
    J Clin Psychiatry; 2010 May; 71(5):528-33. PubMed ID: 20122367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of ondansetron in treating cerebellar tremor in MS patients--an open-label pilot study.
    Gbadamosi J; Buhmann C; Moench A; Heesen C
    Acta Neurol Scand; 2001 Nov; 104(5):308-11. PubMed ID: 11696026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ondansetron versus dolasetron: a comparison study in the prevention of postoperative nausea and vomiting in patients undergoing gynecological procedures.
    Browning BA; Fort CA; Kemp KD; Shimata MF; Strube MD
    AANA J; 2004 Apr; 72(2):129-32. PubMed ID: 15098526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
    Uchiyama S; Ozaki Y; Satoh K; Kondo K; Nishimaru K
    Cerebrovasc Dis; 2007; 24(2-3):264-70. PubMed ID: 17622759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.